From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Small Retrospective Study Suggests Thrombopoietin Receptor Agonists Are Safe, Likely Effective for ITP During...

Preliminary findings from an observational multicenter study suggest that temporary off-label use of thrombopoietin receptor agonists (TPO-RAs) for the treatment of severe and/or refractory...
WIB_icon

ART and PrEP May Present Challenges in Detecting HIV Infection in Blood Donations

While antiretroviral (ARV) drugs and pre-exposure prophylaxis (PrEP) are effective tools to help reduce the burden of HIV, a new study published in Blood...
WIB_icon

Bispecific Immune Cell Engager AFM13 Plus Pembrolizumab Produces High Responses in Heavily Treated Hodgkin...

In a phase Ib study published in Blood, treatment with AFM13, a CD30/CD16A bispecific tetravalent innate immune cell engager, was safe and produced promising...
WIB_icon

Large Study Identifies Predictors of Inferior Survival in Patients With Burkitt Lymphoma

A retrospective analysis of data from 30 U.S. cancer centers found that adults with newly diagnosed Burkitt lymphoma (BL) have modest survival rates and...

Study Supports Earlier, More Frequent Use of Hospice in Older Patients With Hematologic Malignancies

Earlier and more frequent hospice use may be associated with a lower probability of inpatient death and a reduction in aggressive care at end...
WIB_icon

Geriatric Assessment Identifies Risk Factors for Worse Survival in Older Adults With AML

Older patients with acute myeloid leukemia (AML) who undergo post-remission therapy may be at risk of poor survival if they present with impaired physical...
WIB_icon

Inflammatory Biomarkers at Presentation May Predict Thrombosis in COVID-19

Researchers from Massachusetts General Hospital in Boston have identified several markers at presentation that predict coagulation-associated complications in patients with COVID-19: elevated D-dimer, C-reactive...

Examining Toxicities of CAR T-Cell Therapy in Patients With DLBCL

Chimeric antigen receptor (CAR) T-cell therapy has been an important addition to the treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)....

Early FVIII Prophylaxis Improves Long-Term Joint Outcomes in Severe Hemophilia A

Joint bleeding results in acute and chronic pain for patients living with severe hemophilia A, but joint outcomes improve when prophylactic factor VIII (FVIII)...
WIB_icon

Lenzilumab Demonstrates Clinical Benefit in Patients With Chronic Myelomonocytic Leukemia

A phase I study found that lenzilumab, an engineered human IgG1K monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), was associated with a clinical...
Advertisement

Current Issue

September 2020 Volume 6, Issue 11

This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.

Block title